Episode Details

Enlivex, a cell therapy firm, purchases Rain tokens at a significant discount, aiming to bolster its balance sheet and attract investors. The company extends its option to buy more tokens, pushing the deadline to 2027. Rains token price surges post-announcement, while Enlivex shares initially dip but recover in after-hours trading.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/cfe0e00b315cdb7a